Paper Details

  1. Home
  2. Paper Details

GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.

Author: , BorresenT Erik, DietrichDennis W, KnappertzVolker, KolodnyScott, SidiYulia, SteinermanJoshua R, WolinskyJerry S, WynnDaniel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both GA20 and GA40 are effective and safe treatments for relapsing-remitting multiple sclerosis.
Paper Details　
Original Abstract of the Article :
The efficacy and safety of glatiramer acetate (GA) 20 mg/mL once-daily subcutaneous injections (GA20) in relapsing-remitting multiple sclerosis (RRMS) is well-established. However, injection-related adverse events (IRAEs) may impede treatment adherence and tolerability. GA 40 mg/mL three-times weekl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.msard.2015.06.005

データ提供：米国国立医学図書館（NLM）

GLACIER: An Open-Label, Randomized, Multicenter Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg Three-Times Weekly Versus 20 mg Daily

Multiple sclerosis (MS) is a chronic neurological disease that affects the central nervous system. Glatiramer acetate (GA) is an immunomodulatory drug used to treat relapsing-remitting MS (RRMS). This study investigates the safety and tolerability of different dosing regimens of GA in patients with RRMS. Researchers, like explorers charting a new course, are seeking to optimize the delivery of GA to maximize its benefits and minimize its side effects.

Different Dosing Regimens: A Quest for Optimal Delivery

The study, like a meticulously crafted map guiding a caravan through the desert, examines the safety and tolerability of two different GA dosing regimens - 40 mg three times weekly and 20 mg daily. The study found that both regimens demonstrated a favorable safety and tolerability profile, with minimal adverse events reported. This finding is a testament to the ongoing efforts to refine the treatment of RRMS, ensuring the most effective and safe management of this challenging disease.

Health Implications and Applications

This study provides valuable information for clinicians treating patients with RRMS, offering insights into the safety and tolerability of different GA dosing regimens. The finding that both regimens are well-tolerated expands treatment options for patients, allowing clinicians to tailor therapy based on individual patient needs and preferences.

Dr. Camel's Conclusion

This study, like a desert oasis providing respite for weary travelers, offers valuable insights into the safety and tolerability of different GA dosing regimens for RRMS patients. It provides clinicians with valuable information to optimize treatment and improve patient outcomes.

Date :
  1. Date Completed 2016-04-29
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

26195058

DOI: Digital Object Identifier

10.1016/j.msard.2015.06.005

Related Literature

Article Analysis
・Effects of glatiramer injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.